PLAINSBORO, N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART) today announced that it is increasing its 2018 financial outlook in conjunction with its Investor Day meeting on Thursday, November 12, 2015, beginning at 8:30am (ET) in New York City.
During the meeting, Integra’s senior management team will also review the Company’s strategy for growth and product pipeline.
“Our strategy to execute, optimize and accelerate growth has shown results. We are at an inflection point, moving toward a new phase of growth, and today we will update the focus of that strategy and update our 2018 financial outlook,” said Peter Arduini, Integra’s President and Chief Executive Officer. “Beyond 2018, we have opportunities to drive additional margin improvement with scale.”
At the meeting, the Company is raising its expectations for all its key 2018 financial metrics, including the following:
- Organic revenue growth of 6% to 8%;
- Adjusted gross margin of 70% to 71%;
- Adjusted EBITDA margin of about 25%; and,
- Adjusted EPS growth of 12% or more.
As previously announced, the Investor Day presentation will last approximately three and a half hours, including a period for questions and answers, and will be webcast. A link to the Investor Day webcast is available on the Investor Relations homepage of Integra’s website at www.integralife.com. Presentation materials will be available at the same website.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for caregivers, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions and orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2014 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Source:Integra LifeSciences Holdings Corporation